Executive Summary According to the report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271. 3 Million in the year 2020 with North America leading the regional market share.
New York, Jan. 07, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Idiopathic Pulmonary Fibrosis Market – Analysis By Drug Type, End User, By Region, By Country : Market Insights, Pipeline and Forecast with Impact of COVID-19" – https://www.reportlinker.com/p06195732/?utm_source=GNW
The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant’s were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.
Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.
Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient’s symptoms, the stage of the disease, and a patient’s overall health.
Scope of the Report
• The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).
• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).
• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
• The attractiveness of the market has been presented by region, by Drug Class and by End User.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
• The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.
Key Target Audience
• Pharmaceutical and Healthcare Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities
Read the full report: https://www.reportlinker.com/p06195732/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
GameStop's (GME) reported plan to launch an NFT marketplace is "dead on arrival", says one bearish analyst.
The Supreme Court seems to be leaning toward striking down a federal vaccine mandate for large businesses.
(Bloomberg) — U.S. labor board prosecutors are trying to violate Whole Foods Market’s copyright and constitutional rights by forcing it to let employees wear “Black Lives Matter” masks at work, the Amazon.com Inc. subsidiary claims.Most Read from BloombergOmicron Study in South Africa Points to End of Acute Pandemic PhaseU.S. Is Open as Canada Shuts Down. The Difference? Their Health Care SystemsCiti Confronts Vaccine Holdouts in No Jab, No Job MandateBitcoin ETF Goes From Boom to Bust After a
From loss of smell and taste to shortness of breath, we're well aware of the standard symptoms of COVID. But the virus has steadily evolved from its original form, and with it, so have the symptoms it might cause. A new variant called Omicron is estimated to make up more than 95 percent of COVID infection in the U.S. right now, according to the Centers for Disease Control and Prevention (CDC). Doctors are now warning that the signs of this version of the virus may be a little different from the
(Bloomberg) — The highly contagious omicron virus variant is disrupting already stressed food supply chains, sickening so many workers that more shortages at grocery stores are all but certain.Most Read from BloombergOmicron Study in South Africa Points to End of Acute Pandemic PhaseU.S. Is Open as Canada Shuts Down. The Difference? Their Health Care SystemsCiti Confronts Vaccine Holdouts in No Jab, No Job MandateBitcoin ETF Goes From Boom to Bust After a Record U.S. DebutS&P 500 Posts Worst St
With a few notable exceptions, the age of pensions is largely over in the U.S., with traditional defined benefit plans mostly being replaced by defined contribution retirement vehicles like 401(k) plans. A new study from the National Institute on Retirement … Continue reading → The post Pensions May Actually Be Cheaper For Employers Than 401(k) Plans appeared first on SmartAsset Blog.
Oil companies used to compete on how much crude they could produce. Truist analyst Neal Dingmann wrote in a report published Thursday that Exxon looks as if it is going to generate more than enough cash to pay off debt and still have enough to raise its dividend and buyback. The idea that Exxon could raise its dividend had seemed unthinkable just a year ago, because the company looked as if it might have to cut the payout.
Oil companies have had a tough stretch over the past several years. The price of oil, which directly impacts how much money most oil companies make, has fallen from $100 per barrel in 2014 and hasn't yet recovered. Oil prices even temporarily went below zero in 2020!
Amazon's (NASDAQ: AMZN) stock looks like a coiled spring. Pandemic-related gains drove a stunning 76% surge in the online retail giant's share price in 2020. Then its stock essentially treaded water last year on overblown fears that its growth could slow.
Kroger Co. became a player in the Florida grocery market last year — without opening a single store.
Deliveries of the $105,000 electric pickup are expected to start in fall 2023.
The company, which went public in a merger with billionaire Richard Branson's "blank check" company last year, is aiming its cancer immunotherapy drug at solid tumors.
Lululemon is hitting the accelerator at its interactive home gym business even as it readies to defend its digital turf.
As the super contagious variant sweeps across the Lowcountry, what symptoms should residents be monitoring?
Mark Newman, Nomi Health Founder and CEO, joins Yahoo Finance to share how his company worked to make an impact throughout the pandemic.
As Google finalizes plans for a massive cloud engineering hub in Durham, the pressure is heating up for newly tapped site lead Kamala Subramaniam.
Experts agree: It’s time for a more serious mask.
(Bloomberg) — Turkey’s national gas company is trying to raise billions of dollars to pay an import bill due early this year, following a surge in energy prices and a collapse of the lira.Boru Hatlari ile Petrol Tasima AS, known as Botas, has been seeking a loan of around $2 billion to meet looming repayments, with some of the money owed to Russia’s Gazprom PJSC, according to people with knowledge of the matter. It’s only secured around 5 billion liras ($365 million) so far from a group of loca
Anita Louise Jackson, who faces federal charges, also helped lead the COVID-19 response of the Durham County Public Health Department.
Crude oil markets rallied again during the course of the week, only showing signs of hesitation on Friday.